- Trial phase
- Phase 1
- Time to market
- Unknown, early Phase 1; realistically several years from approval if it survives, and most Phase 1 oncology drugs do not reach the market.
- Why 2/10
- NVL-330 is a Phase 1 program inside a ~$100B company with no scheduled PDUFA, pivotal readout, or other dated binary in the next ~12 months, it is a small part of a large pipeline, so it cannot score above 2 on the impact rubric.
For GSK (GSK) investors, NVL-330 is not a tradeable near-term catalyst, ignore it for the next year and instead track GSK's other acquired assets (neladalkib PDUFA Nov 27, 2026; zidesamtinib label expansion) and GSK's Q2-reaffirmed guidance. The only event to watch for NVL-330 specifically is early Phase 1 dose-escalation data at an oncology congress, for which no date was found in any source.
Price Chart
Executive Summary
NVL-330 is a Phase 1 HER2-selective inhibitor for HER2-altered (mutant) non-small cell lung cancer (NSCLC) that GSK plc acquired when it closed its ~$10.6B all-cash takeover of Nuvalent on July 15, 2026 ($124.00/share; Nuvalent, formerly NUVL, is now delisted). It is the third and earliest-stage asset in a targeted-lung-cancer trio GSK bought, alongside zidesamtinib (Jideytro, ROS1+ NSCLC, FDA-approved July 2026) and neladalkib (ALK+ NSCLC, FDA decision expected Nov 27, 2026). For GSK shareholders NVL-330 is currently immaterial to the share price; it matters only as long-option pipeline value.
How It Works
NVL-330 is a daily pill (small-molecule tyrosine kinase inhibitor) designed to block HER2, a cell-growth protein that is abnormally activated by mutations in a subset of lung cancers. By selectively shutting down mutated HER2 while largely sparing closely related proteins, the drug aims to stop HER2-mutant tumors from growing, the same class strategy as GSK's other new lung-cancer assets (which target the ROS1 and ALK growth signals) but aimed at the HER2 mutation.
Trial Status
Phase 1 development for HER2-altered NSCLC, per the June 9, 2026 Nuvalent 8-K describing the GSK deal ("plus a phase I HER2 inhibitor"). No Phase 2/3 ClinicalTrials.gov record, FDA action, or dated readout for NVL-330 exists in the tool data; no clinical data were cited in any source retrieved.
The Two-Sided Case
Upcoming Catalysts
- None dated for NVL-330 itself in the next 12 months (no PDUFA, pivotal readout, or scheduled data presentation found).
- Context catalysts from the same acquired portfolio: neladalkib FDA PDUFA target action date Nov 27, 2026 (per local FDA catalyst data, ticker RPRX royalty stream).
- Any GSK disclosure of NVL-330 Phase 1 dose-escalation/early efficacy data at future oncology conferences, no confirmed date.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GSK plc 6-K GSK ·Originating report